AnaptysBio, Inc. (ANAB) financial statements (2021 and earlier)

Company profile

Business Address 10421 PACIFIC CENTER COURT, SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments394374427248
Cash and cash equivalents25017111481
Short-term investments143203313167
Prepaid expense0   
Other undisclosed current assets3474
Total current assets:397378434253
Noncurrent Assets
Property, plant and equipment2211
Long-term investments and receivables18547376
Long-term investments18547376
Deposits noncurrent assets   0
Restricted cash and investments0000
Other noncurrent assets110 
Total noncurrent assets:20577577
TOTAL ASSETS:417435509329
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1927147
Accounts payable41652
Accrued liabilities151195
Debt 187
Other liabilities0100
Total current liabilities:20302214
Noncurrent Liabilities
Long-term debt and lease obligation  18
Long-term debt, excluding current maturities  18
Liabilities, other than long-term debt 100
Accounts payable and accrued liabilities  00
Other liabilities 1  
Total noncurrent liabilities: 118
Total liabilities:20302322
Stockholders' equity
Stockholders' equity attributable to parent397405486308
Common stock0000
Additional paid in capital661649633393
Accumulated other comprehensive income (loss)(0)0(0)(0)
Accumulated deficit(264)(244)(147)(85)
Total stockholders' equity:397405486308
TOTAL LIABILITIES AND EQUITY:417435509329

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenue, net10
Gross profit:758510
Operating expenses(99)(115)(72)(39)
Operating loss:(24)(107)(67)(29)
Nonoperating income (expense)4105(1)
Investment income, nonoperating   2
Other nonoperating income (expense)(0)0(0)0
Interest and debt expense (1)(2)(2)
Loss from continuing operations before equity method investments, income taxes:(20)(99)(64)(32)
Other undisclosed income from continuing operations before income taxes 122
Loss from continuing operations before income taxes:(20)(97)(62)(30)
Income tax benefit 00 
Net loss available to common stockholders, diluted:(20)(97)(62)(30)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(20)(97)(62)(30)
Other comprehensive income (loss)  0(0)
Comprehensive loss:(20)(97)(61)(30)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)1  
Comprehensive loss, net of tax, attributable to parent:(20)(97)(61)(30)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: